Treatment of postherpetic neuralgia: focus on pregabalin.
Cappuzzo KA.
The Geriatric Pharmacotherapy Program, Virginia Commonwealth University, School of Pharmacy, Richmond, Virginia 23298-0533, USA.kacappuzzo@vcu.edu
Clin Interv Aging. 2009;4:17-23. Epub 2009 May 14.
Abstract
Postherpetic neuralgia (PHN) is a devastating, chronic pain syndrome that can develop following an outbreak of herpes zoster and becomes increasingly common as patients age. PHN can be difficult to treat and often requires trials of multiple agents to achieve significant pain relief. Pregabalin is the newest agent to gain approval for PHN. Data suggest efficacy for relief of pain and sleep disturbance secondary to PHN in affected patients. Although there are no head-to-head comparisons, pregabalin appears comparable to gabapentin and other first-line agents for treating PHN.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685221/pdf/cia-4-017.pdf
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685221/
Cappuzzo KA.
The Geriatric Pharmacotherapy Program, Virginia Commonwealth University, School of Pharmacy, Richmond, Virginia 23298-0533, USA.kacappuzzo@vcu.edu
Clin Interv Aging. 2009;4:17-23. Epub 2009 May 14.
Abstract
Postherpetic neuralgia (PHN) is a devastating, chronic pain syndrome that can develop following an outbreak of herpes zoster and becomes increasingly common as patients age. PHN can be difficult to treat and often requires trials of multiple agents to achieve significant pain relief. Pregabalin is the newest agent to gain approval for PHN. Data suggest efficacy for relief of pain and sleep disturbance secondary to PHN in affected patients. Although there are no head-to-head comparisons, pregabalin appears comparable to gabapentin and other first-line agents for treating PHN.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685221/pdf/cia-4-017.pdf
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685221/
No hay comentarios:
Publicar un comentario